Beam has emerged out of Harvard University with $87m in series A funding to commercialise gene editing technology, with additional research licensed from Broad Institute and Editas Medicine.

Based on research at Johns Hopkins University, Escient Pharmaceuticals is developing treatments for serious but unserved medical needs.

Synthorx's artificial genetic DNA pairings are expected to support the administration of an immuno-oncology drug previously hindered by safety issues.

Cambridge spinout Crescendo Biologics has secured $70m in an IP Group and EMBL Ventures-backed round.

IP Group has committed a total of $6.6m to a series A round for Enterprise Therapeutics, which had previously attracted capital from Touchstone Innovations.

Yale spinout Arvinas has added cash to its coffers as it prepares oncological treatments for forms of prostate and breast cancer.

The immunomodulation therapy developer has been backed by Pablo Legorreta in the wake of a phase 2 trial of its therapy for organ transplant patients.

Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.